Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sophion Bioscience AS

www.sophion.dk

Latest From Sophion Bioscience AS

Are Spin-Outs Really a Better Bet?

Big Pharma spin-outs may on average have raised 50% more private money than non-spin-outs over the last five years, but it's not yet clear whether they always deliver better returns on investment. Still, spin-outs remain an investor favorite, and in Europe are becoming the mainstay of a sustainable biopharma industry.
BioPharmaceutical Strategy

Lectus Therapeutics Ltd.

Lectus was founded in December 2002, to develop and commercialize a second generation of ion channel modulating drugs. By targeting the plethora of accessory proteins that regulate the activity of the ion channel pore-forming proteins rather than the pore-forming proteins themselves Lectus believes its drugs will be safer and more effective than currently marketed products.
BioPharmaceutical Business Strategies

Recent Dealmaking (02/2004)

Summarizing the month in European dealmaking.

Enabling a Comeback in Ion Channel Drug Discovery

Automated medium- and high-throughput ion channel screening systems promise to jump start the search for ion channel modulating drugs, a vast and promising area of drug discovery. In Vivo Europe Rx looks at Sophion Bioscience, Nanion Technologies, and Xention Discovery, three emerging European firms whose platforms may help return ion channels to the forefront of biotech and pharmaceutical companies' discovery targets.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Denmark
  • Parent & Subsidiaries
  • Sophion Bioscience AS
  • Senior Management
  • Torsten Freltoft, PhD, CEO
    Frank Henrichsen, VP, Sales & Mktg.
  • Contact Info
  • Sophion Bioscience AS
    Phone: (45) 4460 8800
    Baltorpvej 154
    Ballerup, DK-2750
    Denmark
UsernamePublicRestriction

Register